Home Cart Sign in  
Chemical Structure| 2138861-99-9 Chemical Structure| 2138861-99-9

Structure of ABBV-744
CAS No.: 2138861-99-9

Chemical Structure| 2138861-99-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ABBV-744 is an inhibitor of BDII-selective BET bromodomain that is being investigated to treat AML and metastic castration-resistant prostate cancer.

Synonyms: ABBV-744

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of ABBV-744

CAS No. :2138861-99-9
Formula : C28H30FN3O4
M.W : 491.55
SMILES Code : O=C(C(N1)=CC(C(C2=CC(C(C)(O)C)=CC=C2OC3=C(C)C=C(F)C=C3C)=CN4C)=C1C4=O)NCC
Synonyms :
ABBV-744
MDL No. :MFCD31657409
InChI Key :OEDSFMUSNZDJFD-UHFFFAOYSA-N
Pubchem ID :132010322

Safety of ABBV-744

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of ABBV-744

epigenetics

Isoform Comparison

Biological Activity

Target
  • BET

In Vitro:

Cell Line
Concentration Treated Time Description References
OCI-AML2 100 nM 2 weeks Identified SPOP as a key gene for BETi resistance PMC10120025
Primary human bronchial epithelial cells 0.01–10 μM 72 h Reduced ACE2 mRNA levels PMC8820466
Calu-3 cells 10 μM 72 h Reduced ACE2 mRNA levels PMC8820466
HGC-27 cells 4.8 μM, 2.3 μM 48h, 72h To evaluate the inhibitory effect of ABBV-744 on the proliferation of HGC-27 cells, the results showed that ABBV-744 significantly inhibited cell survival in a dose- and time-dependent manner. PMC10539879
AGS cells 7.4 μM, 3.5 μM 48h, 72h To evaluate the inhibitory effect of ABBV-744 on the proliferation of AGS cells, the results showed that ABBV-744 significantly inhibited cell survival in a dose- and time-dependent manner. PMC10539879
Orbital fibroblasts (OFs) 10, 100, 500 nM 24 h To evaluate the effect of ABBV744 on TGF-β1-induced fibrosis marker expression, results showed ABBV744 significantly reduced mRNA and protein expression of α-SMA, COL1A1, and COL1A2 PMC10246756

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NSG mice KMT2A-r leukemia xenograft model Oral administration 4.7 mg/kg Daily administration for 3-4 weeks Validated SPOP deficiency causes BETi resistance in vivo PMC10120025
Golden Syrian hamsters SARS-CoV-2 infection model Oral gavage 20 mg/kg Daily for 3 days Reduced SARS-CoV-2 infection PMC8820466
Nude mice BLCA subcutaneous transplantation model Intragastric administration 10 mg/kg Daily for about 3 weeks Combination of ABBV-744 with DDP significantly inhibited tumor growth and increased sensitivity to chemotherapy PMC11571712
Nude mice Subcutaneous tumor model Oral 14 mg/kg 21 days To evaluate the inhibitory effect of ABBV-744 on gastric cancer cell growth in vivo, the results showed that ABBV-744 significantly suppressed tumor growth, and the effect was enhanced when combined with CQ. PMC10539879

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03360006 Acute Myeloid Leukemia (AML) PHASE1 TERMINATED 2020-12-19 UC Irvine /ID# 160789, Orange,... More >> California, 92868, United States|University of California, Davis Comprehensive Cancer Center /ID# 202729, Sacramento, California, 95817, United States|Northwestern /ID# 171098, Chicago, Illinois, 60611, United States|University of Chicago DCAM /ID# 160702, Chicago, Illinois, 60637-1443, United States|Cleveland Clinic Main Campus /ID# 160756, Cleveland, Ohio, 44195, United States|University of Texas MD Anderson Cancer Center /ID# 160701, Houston, Texas, 77030, United States|Swedish-Center for Blood Disor /ID# 166487, Seattle, Washington, 98104, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.03mL

0.41mL

0.20mL

10.17mL

2.03mL

1.02mL

20.34mL

4.07mL

2.03mL

References

 

Historical Records

Categories